Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
$0.18
As of 05/24/2022 IEX book CBOE book
2022 © Stock Market MBA, Inc.